Full text

Turn on search term navigation

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Simple Summary

S-adenosylmethionine (SAMe) is a key molecule involved in cellular methylation and metabolic processes. It plays a crucial role in DNA, RNA and protein methylation, as well as in pathways like polyamine synthesis and transsulfuration. Dysregulation of SAMe metabolism is linked to various cancers, where its depletion leads to genomic instability, abnormal gene expression and tumor progression. Studies suggest SAMe could be a useful cancer biomarker and may enhance treatment by restoring methylation balance, reducing oxidative damage and protecting cells from chemotherapy effects. Targeting SAMe-related pathways, including combination with anticancer drugs, could offer new therapeutic options. Despite its potential, clinical applications remain challenging due to variability in response, poor bioavailability and the complexity of SAMe’s effects across different cancer types. Future research should focus on improving SAMe delivery, identifying biomarkers for patient-specific treatments and integrating SAMe with existing therapies. With further clinical validation, SAMe could become a valuable tool in personalized cancer treatment, helping to improve outcomes and expand therapeutic options.

Details

Title
S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy
Author
Fernández-Ramos, David 1   VIAFID ORCID Logo  ; Fernando Lopitz-Otsoa 2   VIAFID ORCID Logo  ; Lu, Shelly C 3 ; Mato, José M 2   VIAFID ORCID Logo 

 Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain; [email protected] (D.F.-R.); [email protected] (F.L.-O.); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain 
 Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain; [email protected] (D.F.-R.); [email protected] (F.L.-O.) 
 Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; [email protected] 
First page
535
Publication year
2025
Publication date
2025
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3165756890
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.